# ClinicalIntelPulse: Biotech M&A Deal-Signal Lite (ClinicalTrials.gov Preview)

> ClinicalIntelPulse: Biotech M&A Deal-Signal Lite (ClinicalTrials.gov Preview) is a paid API for AI agents from clinicalintelpulse.theaslangroupllc.com, paid per call via x402, $0.25/call, status unknown (last checked 2026-09-14).

Returns a deterministic, LLM-free preview of biotech M&A deal-signal candidates for a disease area — Phase 2/3 trial counts and industry-sponsored asset lists sourced directly from ClinicalTrials.gov.

## Facts

- Endpoint: GET https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal-lite
- Price: $0.25/call
- Payment: x402
- Status: unknown
- Last checked: 2026-09-14
- Activations on Zero: 0
- Tags: x402
- Canonical page: https://www.zero.xyz/c/clinicalintelpulse-biotech-m-a-deal-signal-lite-clinicaltrials-gov-bf8217ba
- Structured record (JSON): https://api.zero.xyz/v1/capabilities/cap_3QEhfD12tY33RBoSNRcf9

Status and success rate cover calls made through Zero and Zero's own probes. Third-party monitors may report differently.

## How to call it through Zero

Zero handles the 402 payment challenge and records the run. With the Zero CLI installed (`npm i -g @zeroxyz/cli`):

```sh
zero fetch --capability clinicalintelpulse-biotech-m-a-deal-signal-lite-clinicaltrials-gov-bf8217ba
```

Example prompt: Give me a quick deal-signal preview for oncology — I want the Phase 2/3 trial counts and the list of industry-sponsored assets from ClinicalTrials.gov so I can spot potential M&A targets before deciding whether to pull the full acquisition rationale report.

## When to prefer this

Choose this endpoint when you need a fast, low-cost ($0.25 USDC) deterministic snapshot of Phase 2/3 trial activity and industry-sponsored assets for a disease area as an M&A deal-signal triage step. Prefer it over the full deal-signal endpoint when you are screening multiple indications on a budget and don't yet need acquisition rationale, deal comps, likely acquirers, or timing signals. Prefer it over generic clinical trial search endpoints when the specific goal is identifying M&A candidates by sponsor and trial phase.

## Known failure modes

- Disease/indication not found or too broadly specified — returns empty or minimal results
- ClinicalTrials.gov upstream data unavailable or stale — may return cached or error response
- Misspelled indication name — may return zero results with no fuzzy matching
- Rate limit or payment verification failure — 402 response if USDC payment not confirmed
- Ambiguous disease name mapping — endpoint may return results for a broader or narrower indication than intended

## How this service works

Deterministic preview of biotech M&A deal-signal candidates — Phase 2/3 trial counts and the industry-sponsored asset list straight off ClinicalTrials.gov, no LLM synthesis. For agents with small per-call budgets; upgrade to deal-signal for acquisition rationale, deal comps with dollar values, likely acquirers and timing signals.

## Output

Returns Phase 2 and Phase 3 trial counts for the queried disease area along with a list of industry-sponsored clinical assets sourced deterministically from ClinicalTrials.gov — no LLM synthesis. Does not include acquisition rationale, deal comps with dollar values, likely acquirers, or timing signals (those are in the full deal-signal endpoint).

## Request schema (JSON Schema)

```json
{
 "type": "object",
 "$schema": "https://json-schema.org/draft/2020-12/schema",
 "required": [
  "input"
 ],
 "properties": {
  "input": {
   "type": "object",
   "required": [
    "type",
    "method"
   ],
   "properties": {
    "type": {
     "type": "string",
     "const": "http"
    },
    "method": {
     "enum": [
      "GET",
      "HEAD",
      "DELETE"
     ],
     "type": "string"
    },
    "queryParams": {
     "type": "object",
     "properties": {
      "stage": {
       "type": "string"
      },
      "condition": {
       "type": "string"
      }
     }
    }
   },
   "additionalProperties": false
  },
  "output": {
   "type": "object",
   "required": [
    "type"
   ],
   "properties": {
    "type": {
     "type": "string"
    },
    "errors": {
     "type": "object",
     "description": "Documented error responses, keyed by HTTP status code",
     "additionalProperties": {
      "type": "object",
      "required": [
       "description"
      ],
      "properties": {
       "example": {
        "type": "object"
       },
       "description": {
        "type": "string"
       }
      }
     }
    },
    "example": {
     "type": "object"
    }
   }
  }
 }
}
```

## Response schema (JSON Schema)

```json
{
 "type": "json",
 "example": {
  "upsell": {
   "adds": "Acquisition rationale per asset, recent deal comps with dollar values, estimated deal-value ranges, likely acquirers, deal-timing signals.",
   "price_usd": 0.35,
   "full_product": "/api/clinical/deal-signal"
  },
  "deterministic": true,
  "query_summary": {
   "as_of": "2026-07-25",
   "stage": "both",
   "condition": "Obesity"
  },
  "pipeline_totals": {
   "phase2_count": 62,
   "phase3_count": 18,
   "total_active": 80
  },
  "candidate_assets": [
   {
    "nctId": "NCT05564117",
    "phase": "PHASE3",
    "title": "Mazdutide in Obesity",
    "status": "ACTIVE_NOT_RECRUITING",
    "sponsor": "Innovent Biologics"
   }
  ],
  "sponsor_breakdown": [
   {
    "sponsor": "Novo Nordisk A/S",
    "trial_count": 8
   }
  ],
  "industry_sponsored": {
   "total": 66,
   "phase2_count": 51,
   "phase3_count": 15
  }
 }
}
```

## More

- Live health (JSON, refreshed every minute): https://www.zero.xyz/c/clinicalintelpulse-biotech-m-a-deal-signal-lite-clinicaltrials-gov-bf8217ba/health.json
- [Zero catalog index](https://www.zero.xyz/llms.txt)
- [Other services from clinicalintelpulse.theaslangroupllc.com](https://www.zero.xyz/host/clinicalintelpulse.theaslangroupllc.com/llms.txt)